Literature DB >> 25466902

Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice.

Magdalena Mazagova1, Lirui Wang1, Andrew T Anfora1, Max Wissmueller1, Scott A Lesley1, Yukiko Miyamoto1, Lars Eckmann1, Suraj Dhungana1, Wimal Pathmasiri1, Susan Sumner1, Caroline Westwater1, David A Brenner1, Bernd Schnabl2.   

Abstract

Translocation of bacteria and their products across the intestinal barrier is common in patients with liver disease, and there is evidence that experimental liver fibrosis depends on bacterial translocation. The purpose of our study was to investigate liver fibrosis in conventional and germ-free (GF) C57BL/6 mice. Chronic liver injury was induced by administration of thioacetamide (TAA) in the drinking water for 21 wk or by repeated intraperitoneal injections of carbon tetrachloride (CCl4). Increased liver fibrosis was observed in GF mice compared with conventional mice. Hepatocytes showed more toxin-induced oxidative stress and cell death. This was accompanied by increased activation of hepatic stellate cells, but hepatic mediators of inflammation were not significantly different. Similarly, a genetic model using Myd88/Trif-deficient mice, which lack downstream innate immunity signaling, had more severe fibrosis than wild-type mice. Isolated Myd88/Trif-deficient hepatocytes were more susceptible to toxin-induced cell death in culture. In conclusion, the commensal microbiota prevents fibrosis upon chronic liver injury in mice. This is the first study describing a beneficial role of the commensal microbiota in maintaining liver homeostasis and preventing liver fibrosis. © FASEB.

Entities:  

Keywords:  bacterial translocation; innate immune system; microbiome

Mesh:

Substances:

Year:  2014        PMID: 25466902      PMCID: PMC4422368          DOI: 10.1096/fj.14-259515

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  64 in total

Review 1.  Host-gut microbiota metabolic interactions.

Authors:  Jeremy K Nicholson; Elaine Holmes; James Kinross; Remy Burcelin; Glenn Gibson; Wei Jia; Sven Pettersson
Journal:  Science       Date:  2012-06-06       Impact factor: 47.728

2.  Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine.

Authors:  C A Rivera; B U Bradford; K J Hunt; Y Adachi; L W Schrum; D R Koop; E R Burchardt; R A Rippe; R G Thurman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-07       Impact factor: 4.052

3.  The gut microbiota as an environmental factor that regulates fat storage.

Authors:  Fredrik Bäckhed; Hao Ding; Ting Wang; Lora V Hooper; Gou Young Koh; Andras Nagy; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

4.  STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity.

Authors:  Won-Il Jeong; Ogyi Park; Svetlana Radaeva; Bin Gao
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

5.  ROS mediates 4HPR-induced posttranscriptional expression of the Gadd153 gene.

Authors:  Wai-Lung Lai; Nai-Sum Wong
Journal:  Free Radic Biol Med       Date:  2005-03-19       Impact factor: 7.376

6.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

7.  Intestinal permeability is increased in patients with advanced cirrhosis.

Authors:  Sonia Pascual; José Such; Angel Esteban; Pedro Zapater; Juan A Casellas; José R Aparicio; Eva Girona; Ana Gutiérrez; Fernando Carnices; Jose M Palazón; Javier Sola-Vera; Miguel Pérez-Mateo
Journal:  Hepatogastroenterology       Date:  2003 Sep-Oct

8.  Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity.

Authors:  Jin Seok Kang; Hideki Wanibuchi; Keiichirou Morimura; Rawiwan Wongpoomchai; Yaowares Chusiri; Frank J Gonzalez; Shoji Fukushima
Journal:  Toxicol Appl Pharmacol       Date:  2007-11-21       Impact factor: 4.219

9.  Toll-like receptor 3 in liver diseases.

Authors:  Shi Yin; Bin Gao
Journal:  Gastroenterol Res Pract       Date:  2010-09-23       Impact factor: 2.260

10.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

View more
  67 in total

Review 1.  Alcoholic liver disease: the gut microbiome and liver cross talk.

Authors:  Phillipp Hartmann; Caroline T Seebauer; Bernd Schnabl
Journal:  Alcohol Clin Exp Res       Date:  2015-05       Impact factor: 3.455

Review 2.  Gut microbiota modulate the immune effect against hepatitis B virus infection.

Authors:  D Xu; Y Huang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-14       Impact factor: 3.267

Review 3.  Human microbiota, blood group antigens, and disease.

Authors:  D Rose Ewald; Susan C J Sumner
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2018-01-09

Review 4.  Intestinal fibrosis: ready to be reversed.

Authors:  Giovanni Latella; Florian Rieder
Journal:  Curr Opin Gastroenterol       Date:  2017-07       Impact factor: 3.287

Review 5.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

6.  Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

Authors:  James H Tabibian; Steven P O'Hara; Christy E Trussoni; Pamela S Tietz; Patrick L Splinter; Taofic Mounajjed; Lee R Hagey; Nicholas F LaRusso
Journal:  Hepatology       Date:  2015-08-10       Impact factor: 17.425

Review 7.  Gut-liver axis at the frontier of host-microbial interactions.

Authors:  Katharina Brandl; Vipin Kumar; Lars Eckmann
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-02-23       Impact factor: 4.052

Review 8.  Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.

Authors:  Phillipp Hartmann; Huikuan Chu; Yi Duan; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-02-15       Impact factor: 4.052

9.  Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West?

Authors:  Nobuhiro Nakamoto; Bernd Schnabl
Journal:  Inflamm Intest Dis       Date:  2016-01-20

Review 10.  Update on the Gastrointestinal Microbiome in Systemic Sclerosis.

Authors:  Chiara Bellocchi; Elizabeth R Volkmann
Journal:  Curr Rheumatol Rep       Date:  2018-06-25       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.